Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.

The present invention relates to a transdermal absorption-type pharmaceutical preparation having improved zonisamide cutaneous permeation. This transdermal absorption-type pharmaceutical preparation is characterized by containing (i) zonisamide or an alkali metal salt thereof and (ii) an ether-type additive containing alpha-monoisostearyl glyceryl ether, monooleyl glyceryl ether, polyoxyethylene lauryl ether, polyoxyethylene oleyl ether, polyoxyethylene alkyl (12-14) ether, polyoxyethylene cetyl...

A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof with the proviso that OSA caused by external mechanical obstruction of the airways such as by mucus is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmu...

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion zonisamide naltrexone topiramate phentermine met...

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions...

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion zonisamide naltrexone topiramate phentermine met...

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion zonisamide naltrexone topiramate phentermine met...

In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion zonisamide naltrexone topiramate phentermine met...